A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
Reason given: Parent study failed to meet the primary endpoint and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints.
Key facts
- Where
- Boca Raton, Cincinnati, Hattiesburg, Lady Lake, Maitland, Manhasset, Neptune City, Phoenix, Port Orange, Portland, Syracuse, Tampa, Washington D.C., Wellington, and Winter Park, United StatesSee the 15 sites
- Phase
- Phase 2
Where in United States
- SFM Clinical Research LLCBoca Raton, United StatesNo longer taking part
- University of Cincinnati Medical CenterCincinnati, United StatesNo longer taking part
- Hattiesburg ClinicHattiesburg, United StatesNo longer taking part
- Charter ResearchLady Lake, United StatesNo longer taking part
- K2 Medical Research - MaitlandMaitland, United StatesNo longer taking part
- Feinstein Institute for Medical ResearchManhasset, United StatesNo longer taking part
- Advanced Clinical InstituteNeptune City, United StatesNo longer taking part
- Banner Alzheimer's InstitutePhoenix, United StatesNo longer taking part
- Progressive Medical Research - ClinEdge - PPDSPort Orange, United StatesNo longer taking part
- Summit Research NetworkPortland, United StatesNo longer taking part
- SUNY Upstate Medical CenterSyracuse, United StatesNo longer taking part
- Axiom Brain Health LLCTampa, United StatesNo longer taking part
- Georgetown University Medical CenterWashington D.C., United StatesNo longer taking part
- Alzheimers Research and Treatment Center - WellingtonWellington, United StatesNo longer taking part
- Conquest Research LLC - Winter Park - ClinEdge - PPDSWinter Park, United StatesNo longer taking part
Trial details
- Who runs it
- Alector Inc.
- Trial code
- NCT05744401
- Record updated
- 25 February 2026
- Original description
A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease.Read full original descriptionShow less
A Multicenter, Long-term Extension Study to Evaluate the Safety, Tolerability, and Efficacy of AL002 in Participants With Alzheimer's Disease
A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease.
Inclusion: Completion of the Planned Treatment Period in the AL002-2 study; The participant is willing and able to give informed consent; Study partner who consents to study participation and who cares for/visits the participant at least 10 hours a week.
Exclusion: Participants deemed not able to provide consent or assent by the Investigator or by local regulations; Participants who were prematurely and permanently discontinued from treatment in the parent study for safety reasons; Participation deemed inappropriate per Investigator discretion.